Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.51 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608464 | 0.91 | GPR119 (0.51) | GPR119FAAHACACBACACACLK2 | |
| SCHEMBL10058390 | 0.90 | GPR119 (0.53) | GPR119DPP4DPP7FAAHACACB | |
| SCHEMBL610276 | 0.90 | GPR119 (0.50) | GPR119FAAHACACBACACA | |
| SCHEMBL608545 | 0.83 | GPR119 (0.39) | GPR119FAAH | |
| SCHEMBL609296 | 0.82 | GPR119 (0.55) | GPR119FAAHACACBACACA | |
| SCHEMBL612473 | 0.79 | GPR119 (0.66) | GPR119 | |
| SCHEMBL612584 | 0.78 | PIK3CD (0.37) | GPR119FAAH | |
| SCHEMBL4106094 | 0.77 | GPR119 (0.83) | GPR119 | |
| SCHEMBL10058417 | 0.77 | GPR119 (0.46) | GPR119DPP4DPP7ACACBACACA | |
| SCHEMBL10058415 | 0.76 | GPR119 (0.47) | GPR119DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885DPP4 217/4885DPP7 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.